アポトーシスを活性化するために癌の駆動体を再接続する
Sai Gourisankar1,2, Andrey Krokhotin1, Wenzhi Ji3
1Department of Pathology, Stanford University, Stanford, CA, USA.
Nature
|July 26, 2023
まとめ
癌細胞死経路を活性化する新しいトランスクリプション/エピジェネティック化学誘導体 (TCIP) を開発した. TCIP1は,耐性型を含む拡散性B細胞リンパ腫を効果的に標的にし,新しい治療戦略を提供します.
科学分野:
- 腫瘍学
- 分子生物学
- 化学生物学
背景:
- 癌細胞は 増殖と生存のために 駆動変異を利用します
- 細胞死経路は通常 細胞を排除して 生物に利益をもたらします
- 既存の癌の誘発因子は 細胞死を誘発するために 潜在的に再接続される可能性があります
研究 の 目的:
- 新種の分子を導入する.トランスクリプション/エピジェネティック・ケミカル・インダクター (TCIP).
- 細胞死遺伝子プロモーターに 癌の誘導因子を誘導する能力を示すために
- 拡散性大B細胞リンパ腫 (DLBCL) の治療におけるTCIPの有効性を調査する.
主な方法:
- 設計されたTCIPは,B細胞リンパ腫6 (BCL6) とBRD4のような転写活性化剤を標的とする小分子と結合する.
- BRD4をBCL6結合部位に誘導する強力な分子であるTCIP1を使用した.
- 遺伝子発現に対するTCIP1の効果とDLBCL細胞系における殺菌効果を評価した.
主要な成果:
- TCIP1は標的遺伝子プロモーターにBRD4結合を強化し,プロアポプト性遺伝子発現を促進した.
- TCIP1は,化学療法抵抗性およびTP53変異性系 (EC50 1~10 nM) を含むDLBCL細胞系を強力に破壊することが示された.
- TCIP1は細胞および組織特異的な効果を示し,複合的転写特異性を強調した.
結論:
- TCIPは癌の内生細胞死経路を活性化するための新しいアプローチです.
- TCIP1は,DLBCLおよび他の悪性腫瘍に対する有意な治療の可能性を示しています.
- TCIPの概念は再生医療や発達障害にも適用できる.
関連する概念動画
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
The Extrinsic Apoptotic Pathway
6.5K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.5K
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Apoptosis
11.6K
Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size...
11.6K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


